HIV Drug Copay Case Spotlights Discriminatory Formulary Issue In Exchange Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
Cigna agrees to cap cost-sharing for some HIV/AIDS drugs at $200 in its exchange plans in Florida as a result of a consent agreement with state regulators. AIDS activists had filed a complaint with HHS alleging Cigna and three other insurers in the state were discriminating against patients with their high copays for HIV/AIDS drugs.
You may also be interested in...
Formulary Oversight For Obamacare Plans Will Be Deferred In Some States
Patient groups raise concerns that states may not be able to monitor formularies for discrimination, limiting patient access to drug coverage.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.